Comparison · NCT01621568-sae
Treatment: Weeks 1-4, Group 1; Weeks 1-2, Group 2 vs No Treatment: Weeks 5-6, Group 1; Week 3, Group 2: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Treatment: Weeks 1-4, Group 1; Weeks 1-2, Group 2 vs No Treatment: Weeks 5-6, Group 1; Week 3, Group 2: serious adverse events. Trial comparisons, record NCT01621568-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01621568-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.927 | 0.806 | 0.975 | wilson | |
| Risk in group 2 | 1 | 0.796 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0732 | -0.194 | 0.136 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.927 | 0.85 | 1.01 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with a serious adverse event on Treatment: Weeks 1-4, Group 1; Weeks 1-2, Group 2 than on No Treatment: Weeks 5-6, Group 1; Week 3, Group 2 | 13.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Treatment: Weeks 1-4, Group 1; Weeks 1-2, Group 2 | Group 1 (Thymoma and thymic carcinoma) treated with sunitinib 50 mg/day, 4 weeks on, 2-weeks off (6 week cycle). | 38 | 41 | EG000 |
| Group 2 | No Treatment: Weeks 5-6, Group 1; Week 3, Group 2 | Group 2 (Thymic carcinoma only) treated with sunitinib 50 mg/day, 2 weeks on, 1 week off (3 week cycle). | 15 | 15 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Date treatment consent signed to date off study, approximately 110 months and 28 days for the thymoma/thymic carcinoma group and 91 months and 11 days for the thymic carcinoma only group.
Source ClinicalTrials.gov
Trial
- Title
- Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
- NCT number
- NCT01621568
- Phases
- PHASE2
- Conditions
- Thymoma, Thymus Neoplasms
- Interventions
- Sunitinib, Sunitinib
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2022-06-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01621568?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01621568-sae